ReviewNeuroscience and biobehavioral reviews2010
Histone modifications, DNA methylation, and schizophrenia.
Review in Neuroscience and biobehavioral reviews, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Dissecting the Epigenetic Changes Induced by Non-Antipsychotic Mood Stabilizers on Schizophrenia and Affective Disorders: A Systematic Review.Frontiers in pharmacology · 2020Pooled it
- Co-expression-based models improve eQTL predictions for transcriptome-wide association studies and highlight new schizophrenia-associated genes.Nature genetics · 2026Article
- Genetic Variants from Large Cohorts and Familial Studies Implicate Common Mechanisms in Schizophrenia.Biology · 2026Review
- Molecular Signatures of Schizophrenia and Insights into Potential Biological Convergence.International journal of molecular sciences · 2025Review
- A comprehensive framework for trans-ancestry pathway analysis using GWAS summary data from diverse populations.PLoS genetics · 2024Article
- Molecular Mechanism Biomarkers Predict Diagnosis in Schizophrenia and Schizoaffective Psychosis, with Implications for Treatment.International journal of molecular sciences · 2023Article
- Pathway-Based Polygenic Risk Scores for Schizophrenia and Associations With Reported Psychotic-like Experiences and Neuroimaging Phenotypes in the UK Biobank.Biological psychiatry global open science · 2023Article
- Patient-Derived In Vitro Models of Microglial Function and Synaptic Engulfment in Schizophrenia.Biological psychiatry · 2022Review
- SEMplMe: a tool for integrating DNA methylation effects in transcription factor binding affinity predictions.BMC bioinformatics · 2022Article
- Chromatin profiling in human neurons reveals aberrant roles for histone acetylation and BET family proteins in schizophrenia.Nature communications · 2022Article
- Differential H3K9me2 heterochromatin levels and concordant mRNA expression in postmortem brain tissue of individuals with schizophrenia, bipolar, and controls.Frontiers in psychiatry · 2022Article
- Genome-wide DNA methylation in an animal model and human studies of schizophrenia: a protocol for a meta-analysis.BMJ open science · 2022Article
- Gadd45 in Neuronal Development, Function, and Injury.Advances in experimental medicine and biology · 2022Review
- Review
- Altered Follicular Fluid Metabolic Pattern Correlates with Female Infertility and Outcome Measures of In Vitro Fertilization.International journal of molecular sciences · 2021Article
- An Exploratory Pilot Study of Changes in Global DNA Methylation in Patients Undergoing Major Breast Surgery Under Opioid-Based General Anesthesia.Frontiers in pharmacology · 2021Article
- Epigenomic Dysregulation in Schizophrenia: In Search of Disease Etiology and Biomarkers.Cells · 2020Review
- Preterm Birth and the Risk of Neurodevelopmental Disorders - Is There a Role for Epigenetic Dysregulation?Current genomics · 2018Review
- Socioeconomic status and the brain: prospects for neuroscience-informed policy.Nature reviews. Neuroscience · 2018Review
- GABAergic inhibitory neurons as therapeutic targets for cognitive impairment in schizophrenia.Acta pharmacologica Sinica · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Studies have demonstrated that several schizophrenia candidate genes are especially susceptible to changes in transcriptional activity as a result of histone modifications and DNA methylation. Increased expression of epigenetic enzymes which generally reduce transcription have been reported in schizophrenia postmortem brain samples. An abnormal chromatin state leading to reduced candidate gene expression can be explained by aberrant coordination of epigenetic mechanisms in schizophrenia. Dynamic epigenetic processes are difficult to study using static measures such as postmortem brain samples. Therefore, we have developed a model using cultured peripheral blood mononuclear cells (PBMCs) capable of pharmacologically probing these processes in human subjects. This approach has revealed several promising findings indicating that schizophrenia subject PBMC chromatin may be less capable of responding to agents which normally 'open' chromatin. We suggest that the ability to appropriately modify chromatin structure may be a factor in treatment response. Several pharmacological approaches for targeting epigenetic processes are reviewed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.